In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only... The post Induction therapy in myeloma: an ever-changing paradigm appeared first on VJHemOnc.
The results from this unplanned, FDA-requested, interim analysis showed that the benefit–risk
profile of pembrolizumab plus lenalidomide and dexamethasone is unfavourable for patients
with newly diagnosed, previously untreated multiple myeloma....
Mohamad Mohty« the benefit–risk profile of pembrolizumab plus lenalidomide and dexamethasone is unfavourable for patients with newly diagnosed, previously untreated multiple myeloma. » (KEYNOTE-185)
@szusmani @SagarLonialMD @VincentRK
New “living drugs”—made from a patient’s own cells—can cure once incurable cancers, Siddhartha Mukherjee writes. But can we afford them?
Mohamad Mohty« Procedures come alive in the tinkering, fussing hands of their operators, who navigate seemingly insurmountable challenges: the bone-marrow transplanter who countenances 83 deaths before mastering the method, the surgeon who figures out how best to... »
- Avancement des CAR-T cells en hématologie : Pr Jason Westin (Houston, USA)- Futur des CAR-T cells en hématologie : Pr Jason Westin (Houston, USA)- Condition des progrès des CAR-T cells en oncologie : Pr Jason Westin (Houston, USA)
Avec le Pr...
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
The impact of the use of antithymocyte globulin (ATG) following a total body irradiation (TBI)–based myeloablative conditioning regimen has been poorly explored. We retrospectively analyzed 724 patients who underwent a first allogeneic hematopoietic...
PubMed comprises more than 29 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.